RFA-CA-23-024: Limited Competition: Cooperative Human Tissue Network (CHTN; UM1 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $800,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on July 7, 2023.
From the official notice on Grants.gov, last changed June 1, 2023. Checked November 7, 2026.
- Award ceiling$800,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUM1
- Clinical trialsNot allowed
- Funded byNCI
- Median yearly award$829,564
- Typical project length10 years
- UM1, Research Project with Complex Structure Cooperative Agreement. A large research project with several connected parts, with substantial NIH involvement. Other open UM1 notices.
Projects funded under RFA-CA-23-024 were run by National Cancer Institute (NCI, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-23-024 in the NIH Guide.
Key dates
| Posted | May 31, 2023 |
|---|---|
| Deadline | July 7, 2023 |
| Archived by Grants.gov | August 12, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $829,564; it allows up to $800,000 per award.
- Most of the money in the 3 programs behind this notice (66% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO), issued by the National Cancer Institute (NCI), is to invite competing continuation applications for cooperative agreement awards from current recipients of the NCI-supported Cooperative Human Tissue Network (CHTN). CHTN with all individual CHTN recipients (referred to as CHTN Divisions) collectively form the CHTN national resource. Presently, the organizational structure of the Network comprises six Divisions. The goal of the CHTN is to collect and distribute to investigators high-quality human tissue specimens to facilitate basic and translational cancer research. Such specimens may be needed for scientific discovery and the development of various molecular diagnostic tests, and prognostic or predictive assays. The CHTN is designed as a unique biospecimen resource in that it is based on the prospective collection and distribution of samples upon specific investigators requests. Samples to be collected from patients include pre-cancerous, malignant, and benign neoplastic tissues, as well as tissues with non-neoplastic diseases and normal tissues. Since its establishment by the NCI in 1987, the CHTN has provided more than 1,350,000 malignant, benign, diseased, and uninvolved (normal adjacent) high-quality human tissue specimens from a wide variety of organ sites to over four thousand investigators.
Funded under RFA-CA-23-024 so far
NIH funded 6 projects under RFA-CA-23-024 in fiscal 2024 to 2026, at 6 institutions. The median yearly award was $829,564.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Cooperative Human Tissue Network Eastern Division | University of Pennsylvania | 2026 | $877,501 |
| Tennessee Valley Cooperative Human Tissue Network | Vanderbilt University Medical Center | 2026 | $1.1 million |
| Biospecimen procurement and tissue microarray manufacture for the CHTN | University of Virginia | 2026 | $419,647 |
| The Cooperative Human Tissue Network Midwestern Division (CHTN MWD) | Ohio State University | 2026 | $810,763 |
| Cooperative Human Tissue Network Support through Duke's BioRepository & Precision Pathology Center | Duke University | 2026 | $717,119 |
| Cooperative Human Tissue Network | Research Inst Nationwide Children's Hosp | 2026 | $829,920 |
Who has won Cancer Biology Research grants before
From fiscal 2021 to 2025, Cancer Biology Research (93.396) awarded $4.3 billion across 3,142 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 70 | $151 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 109 | $144 million |
| Sloan-Kettering Institute for Cancer Research | New York | 66 | $136 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 47 | $107 million |
| The Regents of the University of California, San Francisco | California | 64 | $95.5 million |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Who has won Cancer Detection and Diagnosis Research grants before
From fiscal 2021 to 2025, Cancer Detection and Diagnosis Research (93.394) awarded $2.7 billion across 1,944 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 56 | $114 million |
| Fred Hutchinson Cancer Center | Washington | 37 | $96.7 million |
| The Leland Stanford Junior University | California | 62 | $89.1 million |
| Sloan-Kettering Institute for Cancer Research | New York | 52 | $88.7 million |
| The Johns Hopkins University | Maryland | 63 | $86.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-23-024 still open?
No. It closed on July 7, 2023.
Who can apply for Limited Competition: Cooperative Human Tissue Network (CHTN; UM1 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Limited Competition: Cooperative Human Tissue Network (CHTN; UM1 Clinical Trial Not Allowed)?
Closed July 7, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $800,000 each.
Who has been funded under RFA-CA-23-024?
NIH RePORTER lists 6 projects funded under RFA-CA-23-024 in fiscal 2024 to 2026, at 6 institutions. The most were at University of Pennsylvania, Vanderbilt University Medical Center, University of Virginia.
Who has won Cancer Cause and Prevention Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.
Similar open grants
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)
- Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)
- Cellular Senescence Network (SenNet): SenNet Data Coordination and Integration Center (SenNet DCIC) (UM1 Clinical Trials Not Allowed)
- Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)
- Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, Clinical Trial Not Allowed)